# Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure

> **NCT01970501** · PHASE2 · COMPLETED · sponsor: **ARCA Biopharma, Inc.** · enrollment: 267 (actual)

## Conditions studied

- Current or Recent History of Atrial Fibrillation

## Interventions

- **DRUG:** bucindolol hydrochloride
- **DRUG:** metoprolol succinate
- **OTHER:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT01970501
- **Lead sponsor:** ARCA Biopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2017-12-28
- **Final completion:** 2017-12-28
- **Target enrollment:** 267 (ACTUAL)
- **Last updated:** 2022-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01970501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01970501, "Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01970501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*